Welcome to our dedicated page for Phreesia SEC filings (Ticker: PHR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Phreesia, Inc. (NYSE: PHR) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors analyze how Phreesia reports its financial performance, material events and key agreements related to its healthcare technology and patient activation business.
Phreesia’s filings include Current Reports on Form 8-K that describe significant developments such as quarterly financial results, material definitive agreements and acquisitions. For example, the company has filed 8-Ks covering its fiscal quarter results, the Agreement and Plan of Merger to acquire AccessOne Parent Holdings, Inc., and the completion of that acquisition, which made AccessOne a wholly owned subsidiary. Other 8-Ks detail the bridge loan credit agreement, amendments to its credit facility with Capital One and the voting results of its annual meeting of stockholders.
Through this page, users can also locate annual reports on Form 10-K and quarterly reports on Form 10-Q (when available in the broader filing set), which typically contain segment information for subscription and related services, payment processing fees and network solutions, along with discussions of non-GAAP measures such as Adjusted EBITDA. Proxy materials and governance-related filings provide additional context on board elections, auditor ratification and executive compensation votes.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, explain complex sections and surface items such as new debt obligations, acquisition terms or changes to credit agreements. Real-time updates from EDGAR, combined with simplified explanations, make it easier to track Phreesia’s regulatory history, capital structure and major corporate actions without reading every page of each filing.
Phreesia, Inc. director Jon Kessler filed an initial Form 3, which is a required statement of beneficial ownership for insiders. The filing identifies him as a director of Phreesia but does not report any stock transactions or derivative positions, serving as a baseline disclosure of his insider status.
Phreesia, Inc. reported solid fourth-quarter fiscal 2026 results but reduced its revenue outlook for fiscal 2027. Q4 revenue was $127.1 million, up 16% year-over-year, led by payment solutions and the AccessOne acquisition, with adjusted EBITDA of $29.4 million and a 23% margin.
For fiscal 2026, Phreesia surpassed $100 million in adjusted EBITDA, generated over $50 million in free cash flow, and delivered its first full-year positive GAAP net income. Management now expects fiscal 2027 revenue of $510–$520 million, down from a prior $545–$559 million range, mainly due to weaker visibility and lower commitments from certain pharmaceutical and public health clients in its network solutions business, while maintaining adjusted EBITDA guidance of $125–$135 million.
Pale Fire Capital SICAV a.s., as part of a group of reporting persons, bought a total of 1,275,500 shares of Phreesia, Inc. common stock in open-market transactions over three days. Purchases occurred on March 31, April 1 and April 2 at weighted average prices of about $8.16, $8.43 and $8.31 per share. Following these transactions, PFC SICAV indirectly held 8,924,329 Phreesia shares. Other affiliated entities and individuals may be deemed to beneficially own these securities through control relationships, but they disclaim beneficial ownership beyond their pecuniary interests.
Phreesia, Inc. investor Pale Fire Capital, through affiliated Czech entities and individuals, has amended its Schedule 13D to update its stake in the company. The group reports beneficial ownership of 8,924,329 shares of common stock, representing 14.7% of Phreesia’s outstanding shares based on 60,763,065 shares outstanding as of March 25, 2026.
The filing states that the shares held by PFC SICAV were acquired using working capital, which can include margin loans from brokerage firms, for an aggregate purchase price of approximately $103,476,772, including commissions. Several related entities and individuals, including Pale Fire Capital and its key principals, may be deemed to share voting and dispositive power over these shares, although each expressly disclaims beneficial ownership of securities not directly owned.
Phreesia, Inc. provides an integrated software, payments and patient-engagement platform that supports access, affordability and outcomes across the U.S. healthcare system. In fiscal 2026, its platform supported about 180 million patient visits, roughly one in six ambulatory visits in the United States.
The company reports a diversified revenue model from subscription and related services, payment solutions and Network Solutions, and estimates a $24 billion total addressable market across these lines. Phreesia completed the AccessOne acquisition to expand healthcare payment and financing capabilities, operates fully remotely with 1,789 employees, and highlights extensive regulatory, cybersecurity, competition, AI, financing and privacy risks that could materially affect future results.
Phreesia reported a strong turnaround for fiscal 2026, achieving profitability and robust cash generation. Fiscal-year revenue reached $480.6 million, up 14% year-over-year. Net income was $2.3 million, compared with a $58.5 million loss in fiscal 2025, while Adjusted EBITDA rose to $101.5 million from $36.8 million.
Free cash flow improved to $54.4 million from $8.3 million, supported by operating cash flow of $78.8 million. In the fourth quarter, revenue was $127.1 million, up 16%, with net income of $1.3 million and Adjusted EBITDA of $29.4 million. The company closed the $164 million AccessOne Acquisition and later refinanced its $110 million Bridge Loan into a new $275 million, five-year senior secured revolving credit facility.
For fiscal 2027, Phreesia lowered its revenue outlook to $510–$520 million from $545–$559 million, citing lower second-half commitments from certain pharmaceutical network solutions clients, but maintained its Adjusted EBITDA target of $125–$135 million. Management expects continued operating leverage, aided by AI-driven efficiency initiatives, and mid-single-digit AHSC growth with lower revenue-per-client growth.
Phreesia, Inc.’s Chief Financial Officer Balaji Gandhi reported a small, tax-related share sale. On the reported date, he disposed of 3,829 shares of common stock at a weighted average price of $11.2635 per share. A footnote explains these were non-discretionary transactions under the company’s mandatory sell-to-cover policy to satisfy tax withholding on settling restricted stock units, rather than elective open‑market sales. After this activity, he directly held 146,740 shares.
Phreesia Inc ownership update: The Vanguard Group filed an Amendment No. 4 to Schedule 13G/A stating it beneficially owns 0 shares of Phreesia Inc common stock, representing 0% of the class. The filing explains an internal realignment on January 12, 2026 that led certain Vanguard subsidiaries to report holdings separately.
Phreesia, Inc. General Counsel & Secretary Allison C. Hoffman reported an open-market sale of 6,176 shares of Phreesia common stock at $11.97 per share on March 23, 2026. After this transaction, she directly holds 163,485 shares of Phreesia common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 19, 2025, indicating the trade was scheduled in advance rather than timed discretionarily.
PHR filed a Form 144 reporting a proposed sale of Common shares tied to a restricted stock vesting. The filing lists 3,829 shares with an effective/offer date of 03/24/2026 and indicates the broker Fidelity Brokerage Services LLC for transactions on 03/25/2026.
The filing also discloses prior sales by Balaji Gandhi in the past three months: 8,009, 975, and 4,687 shares on 01/08/2026, 01/15/2026, and 01/16/2026, respectively.